Advertisement
Screener

SCYNEXIS, Inc. (SCYX) Revenue, Net (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

SCYNEXIS, Inc. Revenue, Net (Deprecated 2018-01-31)

SCYNEXIS, Inc. (SCYX) reported Revenue, Net (Deprecated 2018-01-31) of $2.31 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-15.

Discontinued › Income Statement › Revenue

us-gaap:SalesRevenueNet · last filed 2015-05-15

  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $2.31M, a 19.88% decline year-over-year.
  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $3.48M, a 87.74% increase year-over-year.
  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $2.56M, a 9.27% increase year-over-year.
  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $2.82M, a 17.30% increase year-over-year.
  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for fiscal 2014 was $11.74M, a 22.65% increase from fiscal 2013.
  • SCYNEXIS, Inc. revenue, net (deprecated 2018-01-31) for fiscal 2013 was $9.57M.
Period endRevenue, Net (Deprecated 2018-01-31) 3 monthRevenue, Net (Deprecated 2018-01-31) 6 monthRevenue, Net (Deprecated 2018-01-31) 9 monthRevenue, Net (Deprecated 2018-01-31) 12 month
2015-03-31$2.31M
10-Q · filed 2015-05-15
$5.79M
derived: sum of 2 quarters · filed 2015-05-15
$8.34M
derived: sum of 3 quarters · filed 2015-05-15
$11.16M
derived: sum of 4 quarters · filed 2015-05-15
2014-12-31$3.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
$6.03M
derived: sum of 2 quarters · filed 2015-03-30
$8.85M
derived: sum of 3 quarters · filed 2015-03-30
$11.74M
10-K · filed 2015-03-30
2014-09-30$2.56M
10-Q · filed 2014-11-13
$5.38M
derived: sum of 2 quarters · filed 2014-11-13
$8.26M
10-Q · filed 2014-11-13
$10.11M
derived: sum of 4 quarters · filed 2015-05-15
2014-06-30$2.82M
10-Q · filed 2014-08-13
$5.70M
10-Q · filed 2014-08-13
$7.55M
derived: sum of 3 quarters · filed 2015-05-15
$9.89M
derived: sum of 4 quarters · filed 2015-05-15
2014-03-31$2.88M
10-Q · filed 2015-05-15
$4.73M
derived: sum of 2 quarters · filed 2015-05-15
$7.08M
derived: sum of 3 quarters · filed 2015-05-15
$9.48M
derived: sum of 4 quarters · filed 2015-05-15
2013-12-31$1.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
$4.19M
derived: sum of 2 quarters · filed 2015-03-30
$6.60M
derived: sum of 3 quarters · filed 2015-03-30
$9.57M
10-K · filed 2015-03-30
2013-09-30$2.34M
10-Q · filed 2014-11-13
$4.75M
derived: sum of 2 quarters · filed 2014-11-13
$7.72M
10-Q · filed 2014-11-13
2013-06-30$2.40M
10-Q · filed 2014-08-13
$5.38M
10-Q · filed 2014-08-13
2013-03-31$2.97M
10-Q/A · filed 2014-07-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
VERU INC. (VERU)United States$0.043B-3.93
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98